In this short video, Tracy Weslosky of InvestorIntel interviews Chris Thompson of eResearch about eResearch’s Update Report on Xortx Therapeutics pertaining to the Company’s recent $21 million financing and U.S. listing. [more]
New 25-page Update Equity Research Report on XORTX, with a Buy rating and one-year price target of $26.00/share. The Company has two potential late-stage drugs in development focused on kidney diseases with one drug that could be approved within the next 18 months and the other drug that could have an orphan drug indication on the market in 2025. [more]
Investors inject cash into Eupraxia Pharmaceuticals during its IPO on the TSX. The funds will be used to support clinical trials of their leading knee osteoarthritis treatment. Eupraxia’s polymer technology promises to flatten the drug-dose curve, providing long-term pain relief (up to 6 months) with fewer side effects. [more]
Copyright © 2024 | MH Magazine WordPress Theme by MH Themes